A Study on the Safety and Efficacy of Riliprubart in Participants with Chronic Inflammatory Demyelinating Polyneuropathy Who Are Not Responding to Standard Treatments
Descrizione riassuntiva dello studio
The aim of this study is to find out whether a new medication called Riliprubart works in people with CIDP whose condition has not improved under standard treatments. The study will also ensure that Riliprubart is safe for the individuals receiving it.
(BASEC)
Intervento studiato
This study investigates Riliprubart. It is a type of medication that prevents a specific part of the body's immune system from being overly active. A placebo (dummy medication) will also be used in the study. The placebo looks like the medication being studied – however, it contains no active ingredient. Therefore, it is also called a 'dummy medication.' In the first part of the study, it will be determined how well Riliprubart improves disability compared to a placebo treatment. In the second part, it will be assessed how well Riliprubart works to improve disability in the long term.
(BASEC)
Malattie studiate
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare condition in which the body's immune system attacks the myelin that surrounds and protects the nerves. People with CIDP typically suffer from muscle weakness, making it difficult for them to walk. They may also experience strange sensations such as tingling, numbness, or coordination difficulties. This often leads to increasing disability, which may require physical therapy, special devices like braces, or even a wheelchair.
(BASEC)
I 02. The participant must have CIDP or possible CIDP criteria. I 03. The participant must be refractory (non-responsive) to either immunoglobulin therapy or corticosteroid therapy. I 05. All permitted immunosuppressants (azathioprine, ciclosporin, or mycophenolate mofetil) must have been taken at a stable dose for ≥6 months before screening. I 06. The participant may receive low-dose oral corticosteroids, but only if they have been taken at a stable dose for ≥3 months before screening. I 08. The participant must have documented vaccinations against encapsulated bacterial pathogens [Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae] within 5 years prior to screening or have the vaccinations initiated at least 14 days before the first dose of the investigational product. (BASEC)
Criteri di esclusione
E 01. Polyneuropathy of other causes. E 03. Any other neurological or systemic disease that may cause symptoms and signs that could interfere with treatment or outcome assessment. E 04. Poorly controlled diabetes (HbA1c > 7%). E 05. Severe infections. E 12. The participant has received immunoglobulins (IVIg or SCIg) within 8 weeks prior to screening. E 13. Treatment with plasma exchange within 8 weeks prior to screening. (BASEC)
Luogo dello studio
Berna
(BASEC)
Sponsor
Sanofi-aventis (suisse) sa 3, Route de Montfleury 1214 Vernier
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Hanka Klaus
+49 (0)30 2575 2442
CSU-CTA-EK@cluttersanofi.comSanofi-aventis (suisse) sa 3, Route de Montfleury 1214 Vernier
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione d'etica Berna
(BASEC)
Data di approvazione del comitato etico
27.08.2024
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
A Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile